Does Covid-19 vaccine increase White Fibrous Clots?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Was this fact-check helpful?
1. Summary of the results
The claim that Covid-19 vaccines increase White Fibrous Clots is a topic of ongoing research and debate. According to [1], COVID-19 patient fibrinogen produces dense clots with altered polymerization kinetics, which could be related to the increased risk of White Fibrous Clots [1]. However, this study does not specifically address the link between Covid-19 vaccines and White Fibrous Clots. On the other hand, [2] reports a modest increase in overall blood clot risk after mRNA COVID‑19 vaccination, including arterial thrombosis, which may raise the incidence of white (fibrous) clots, though the effect size is small [2]. Additionally, [3] notes a higher risk of arterial clots after the AstraZeneca vaccine, at about 10 cases per million doses, which could be related to White Fibrous Clots [3]. The FDA VAERS analysis of the Ad26.COV2.S (Janssen) vaccine also identifies numerous reports of arterial clot events, suggesting a potential increase in white fibrous clots following this vaccine [4]. However, it is essential to note that causality is not established in these reports. In contrast, [5] directly addresses the claim and states that according to health authorities in Thailand, the 'white clots' are commonly found in bodies of the deceased and are not related to mRNA vaccines [5].
2. Missing context/alternative viewpoints
Several key points are missing from the original statement. Firstly, the definition and characteristics of White Fibrous Clots are not provided, making it challenging to understand the context of the claim [1]. Secondly, the mechanism by which Covid-19 vaccines could potentially increase the risk of White Fibrous Clots is not explained [2]. Additionally, the overall risk-benefit analysis of Covid-19 vaccines is not considered, which is crucial in understanding the significance of the potential increase in White Fibrous Clots [2]. Alternative viewpoints, such as the natural occurrence of White Fibrous Clots in the general population, are also not discussed [5]. Furthermore, the differences in risk between various Covid-19 vaccines are not addressed, which could be essential in understanding the claim [3]. The role of underlying health conditions in the development of White Fibrous Clots is also not considered [1].
3. Potential misinformation/bias in the original statement
The original statement may be misleading as it implies a direct link between Covid-19 vaccines and White Fibrous Clots, which is not entirely supported by the available evidence [5]. The statement may benefit anti-vaccination groups by creating unnecessary fear and mistrust towards Covid-19 vaccines [5]. On the other hand, the statement may not benefit public health efforts as it may lead to vaccine hesitancy and reduced vaccination rates, which could have severe consequences for individuals and communities [2]. The pharmaceutical industry may also be affected by the statement, as it could impact the sales and development of Covid-19 vaccines [4]. Ultimately, it is essential to consider multiple sources and viewpoints to form a comprehensive understanding of the claim and its implications [1] [2] [5].